Matarin Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Matarin Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$3.26M	Sell	129,607 -59,271	-31%	-$1.28M	0.8%	43
2020 Q3	$3.94M	Sell	188,878 -27,865	-13%	-$632K	0.83%	41
2020 Q2	$5.15M	Sell	216,743 -171,242	-44%	-$3.78M	1.03%	17
2020 Q1	$6.98M	Sell	387,985 -21,923	-5%	-$461K	1.08%	11
2019 Q4	$9.72M	Sell	409,908 -13,322	-3%	-$324K	0.93%	21
2019 Q3	$11.6M	Buy	423,230 +305,082	+258%	+$9.04M	0.88%	36
2019 Q2	$3.91M	Buy	+118,148	New	+$4.05M	0.28%	133

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return

Matarin Capital Management's SUPN Position: Q4 2020 in Review

Matarin Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 31% in Q4 2020, selling an estimated $1.28M and leaving 129,607 shares worth $3.26M. The position accounts for 0.8% of the portfolio, ranked #43.

Matarin Capital Management first reported a position in SUPN in Q2 2019 and has held it in 7 quarters since. The position peaked at $11.6M in Q3 2019. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

Matarin Capital Management held 129,607 shares of Supernus Pharmaceuticals worth $3.26M as of Q4 2020.
Matarin Capital Management sold 59,271 Supernus Pharmaceuticals shares in Q4 2020, an estimated $1.28M.
Supernus Pharmaceuticals made up 0.8% of Matarin Capital Management's portfolio in Q4 2020, its #43 holding.
Matarin Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2019 and has held it in 7 quarters since.
Matarin Capital Management's Supernus Pharmaceuticals position peaked at $11.6M in Q3 2019.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.